Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide

The success of allogeneic hematopoietic cell transplantation (HCT) is based on survival that is free of morbidity and mortality, allowing for a good quality of life for surviving patients. The long-term need for immunosuppression (IS) for control of chronic graft-versus-host disease (GVHD) has a significant impact on quality of life and is considered one of the main morbidities hindering the success of allogeneic HCT [1 –3].

Source: Biology of Blood and Marrow Transplantation - March 27, 2024 Category: Hematology Authors: Melhem Solh, Asad Bashey, Xu Zhang, H. Kent Holland, Lizamarie Bachier-Rdriguez, Lawrence E. Morris, Scott R. Solomon Tags: Full-Length Article Source Type: research